Procalcitonin: The Right Answer but to Which Question?

Clinical Infectious Diseases

Volumn 65, Issue 2, 2017, Pages 191-193

  Bergin, Stephen P ^a,b   Tsalik, Ephraim L ^a,b,c  

^a Center for Applied Genomics and Precision Medicine   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

Author keywords

pneumonia; procalcitonin; respiratory tract infections.

Indexed keywords

ANTIBIOTIC AGENT; PROCALCITONIN; CALCITONIN;

ANTIBIOTIC THERAPY; CLINICAL TRIAL (TOPIC); COMMUNITY ACQUIRED PNEUMONIA; HOST; HUMAN; NOTE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; ADULT; COMMUNITY ACQUIRED INFECTION; PNEUMONIA;

ADULT; CALCITONIN; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; PNEUMONIA; PROCALCITONIN;

EID: 85023185604     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix323     Document Type: Note

References (14)

1. Self WH, Balk RA, Grijalva CG, et al. Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia. Clin Infect Dis 2017; 65:183-90
2. Jain S, Williams DJ, Arnold SR, et al; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med 2015; 372:835-45
3. Creer DD, Dilworth JP, Gillespie SH, et al. Aetiological role of viral and bacterial infections in acute adult lower respiratory tract infection (LRTI) in primary care. Thorax 2006; 61:75-9
4. Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010-2011. JAMA 2016; 315:1864-73
5. Schuetz P, Müller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012; 9:CD007498
6. Schuetz P, Christ-Crain M, Thomann R, et al; ProHOSP Study Group. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302:1059-66
7. US Food and Drug Administration. In: US Department of Health and Human Services, ed. FDA clears test to help manage antibiotic treatment for lower respiratory tract infections and sepsis. 2017. Available at: www.accessdata.fda.gov. Accessed 18 March 2017
8. Schuetz P, Maurer P, Punjabi V, Desai A, Amin DN, Gluck E. Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients. Crit Care 2013; 17:R115
9. Becker KL, Nylén ES, White JC, Müller B, Snider RH Jr. Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004; 89:1512-25
10. Gilbert DN. Use of plasma procalcitonin levels as an adjunct to clinical microbiology. J Clin Microbiol 2010; 48:2325-9
11. Melendi GA, Laham FR, Monsalvo AC, et al. Cytokine profiles in the respiratory tract during primary infection with human metapneumovirus, respiratory syncytial virus, or influenza virus in infants. Pediatrics 2007; 120:e410-5
12. Tsalik EL, Henao R, Nichols M, et al. Host gene expression classifiers diagnose acute respiratory illness etiology. Sci Transl Med 2016; 8:322ra11
13. Suarez NM, Bunsow E, Falsey AR, Walsh EE, Mejias A, Ramilo O. Superiority of transcriptional profiling over procalcitonin for distinguishing bacterial from viral lower respiratory tract infections in hospitalized adults. J Infect Dis 2015; 212:213-22
14. Tsalik EL, Petzold E, Kreiswirth BN, et al; and the Diagnostics and Devices Committee of the Antibacterial Resistance Leadership Group. Advancing diagnostics to address antibacterial resistance: the Diagnostics and Devices Committee of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017; 64(suppl. 1):41-7